Equity Research
In this interview with the Boston affiliate of NPR – WBUR – research analyst Myles Minter shares his insights on the long-term value, if any, of one COVID-19 vaccine producer, in this case Moderna, being first to market with an approved vaccine for children under the age of five.
Stay up-to-date with the latest William Blair news
William Blair & Company acted as the exclusive financial advisor to Prime Trust in connection with its $107 million Series B financing.
Read moreWilliam Blair acted as lead financial advisor to Brightly Software, Inc., a portfolio company of Clearlake Capital Group, L.P., in connection with its pending sale to Siemens AG (FRA:SIE) for $1.575 billion of upfront cash consideration, along with $300 million in cash earn-out payments, for a total of $1.875 billion.
Read moreWilliam Blair & Company acted as the lead financial advisor to BlueCat, a portfolio company of Madison Dearborn Partners, LLC (MDP) in connection with its pending acquisition by Audax Group.
Read moreInformation contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures
